Who are nab-paclitaxel combined with carboplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antiandrogen+docetaxel, Immune checkpoint inhibitors or docetaxel, Docetaxel + Standard dose Vitamin D2, Placebo, Trastuzumab, Docetaxel, Genexol®, Bevacizumab and Paclitaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nab-paclitaxel-combined-with-carboplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

nab-paclitaxel combined with carboplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

nab-paclitaxel combined with carboplatin (nab-paclitaxel combined with carboplatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane chemotherapy. Area: Oncology.

phase 3 Taxane chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

nab-paclitaxel combined with carboplatin (nab-paclitaxel combined with carboplatin) — Women's Hospital School Of Medicine Zhejiang University. Nab-paclitaxel is a chemotherapy medication that works by inhibiting cell division, while carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
nab-paclitaxel combined with carboplatin TARGET	nab-paclitaxel combined with carboplatin	Women's Hospital School Of Medicine Zhejiang University	phase 3	Taxane chemotherapy
Antiandrogen+docetaxel	Antiandrogen+docetaxel	Göteborg University	phase 3	Combination therapy: androgen receptor antagonist + taxane chemotherapy	Androgen receptor (AR) and microtubule-associated proteins
Immune checkpoint inhibitors or docetaxel	Immune checkpoint inhibitors or docetaxel	NovoCure GmbH	phase 3	Combination therapy (checkpoint inhibitor + taxane chemotherapy)
Docetaxel + Standard dose Vitamin D2	Docetaxel + Standard dose Vitamin D2	King Faisal Specialist Hospital & Research Center	phase 3	Taxane chemotherapy + vitamin supplement	β-tubulin (docetaxel); vitamin D receptor (vitamin D2)
Placebo, Trastuzumab, Docetaxel	Placebo, Trastuzumab, Docetaxel	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Monoclonal antibody + taxane chemotherapy combination	HER2 (trastuzumab); tubulin (docetaxel)
Genexol®	Genexol®	Samyang Biopharmaceuticals Corporation	phase 3	Taxane chemotherapy (nanoparticle albumin-bound)	Microtubule stabilization (paclitaxel mechanism)
Bevacizumab and Paclitaxel	Bevacizumab and Paclitaxel	Central European Cooperative Oncology Group	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy	VEGF (bevacizumab); beta-tubulin (paclitaxel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane chemotherapy class)

Sung Yong Oh · 1 drug in this class
Women's Hospital School Of Medicine Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nab-paclitaxel combined with carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/nab-paclitaxel-combined-with-carboplatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab